New combo therapy targets resistant prostate cancer
Disease control
Completed
This early-stage study tested a new drug, ARV-110, combined with the standard treatment abiraterone in 45 men with metastatic prostate cancer whose PSA levels were rising despite abiraterone alone. The main goals were to check safety and find the best dose. The study is complete,…
Phase: PHASE1 • Sponsor: Arvinas Androgen Receptor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC